IGF2 and metabolic dysfunction-associated steatohepatitis: We found that SRSF3 levels were reduced in NASH‐associated HCC, which agrees with other studies reporting loss or functional inhibition of SRSF3 in HCC,[4, 5, 6] and inversely correlated with IGF2 levels.